The development of brain-computer interface (BCI) technologies in China is currently at a stage of active growth and occupies a significant place in both medicine and high technologies, reports Kazinform, citing information from Xinhua.
In recent years, Chinese researchers have significantly accelerated progress in this field. Starting from 2025, a number of innovative developments are set to emerge from laboratories and find practical applications, showing positive results in the treatment of various diseases.
One of the outstanding achievements has been the domestic systems "Beinao-1" and "Beinao-2". Specialist Zhao Jizong reported that the semi-invasive system "Beinao-1" has been successfully implanted in seven patients, allowing them to restore motor and speech functions after rehabilitation. At the same time, "Beinao-2" will soon begin clinical trials.
The brain-computer interface creates a direct connection between the human brain and external devices. These systems read and interpret brain signals, enabling patients to control prosthetics, computers, and other assistive devices, which is especially important for people with severe motor limitations.
The government's support for the development of BCIs is significant. This technology has been designated as a priority direction during the two sessions, where it has been allocated a place in the list of future industries. At the same time, specialized clinics and research centers are actively being established in major cities such as Beijing, Tianjin, Guangzhou, Wuhan, and Nanjing.
Among the important achievements is the approval of the world's first invasive medical device based on BCI, designed to assist patients suffering from tetraplegia caused by spinal cord injury. This device helps partially restore the functions of the hands and fingers.
The relevance of such technologies is hard to overestimate, considering the scale of the problem. According to experts, more than 3.7 million people in China have spinal cord injuries. In addition, BCIs are seen as a promising solution for treating Parkinson's disease, strokes, epilepsy, and amyotrophic lateral sclerosis.
Thus, China is focusing on BCIs as a strategic area capable of changing the approach to treating neurological diseases and improving the interaction between humans and technology.
